期刊文献+

妇科恶性肿瘤患者凝血功能变化及其临床意义 被引量:7

The changes of coagulation function and its clinical significance in patients with gynecologic malignant tumor
下载PDF
导出
摘要 目的:研究妇科恶性肿瘤患者5项凝血指标的变化及其临床意义。方法:术前测定101例妇科恶性肿瘤患者(宫颈癌28例,卵巢癌35例,子宫内膜癌38例)的血小板(PLT)、血浆凝血酶原时间(PT)、部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)并与89例妇科良性肿瘤患者(子宫肌瘤45例,卵巢囊肿44例)进行比较。结果:妇科恶性肿瘤患者的FIB及PLT水平与妇科良性肿瘤组相比明显增高(P<0.01);而APTT、PT、TT水平与妇科良性肿瘤组相比差异无统计学意义(P>0.05),同时分期为Ⅲ~Ⅳ期晚期恶性肿瘤患者的血浆FIB及PLT水平均高于Ⅰ~Ⅱ期的患者(P<0.01)。结论:妇科恶性肿瘤患者体内存在着异常的血液高凝状态。 Objective: To study the changs of coagulation parameter in patients with gynecologic malignant tumor and its clinical significance.Methods: Detect the PLT,PT,APTT,TT and FIB levels of 101 gynecologic malignan tumors(including 28 cervical carcinomas,35 ovarian carcinomas,38 uterus intimal carcinomas) and 89 gynecologic tumors(inciuding 45 uterine myomas,44 oarian cysts).Results: As compared with normal terms,APTT,PT and TT were no significanty different while FIB and PLT were significantly higher(P〈0.01)in gynecologic malignant tumor patients.FIB and PLT of term Ⅲ to Ⅳ were higher than that in term Ⅰ to Ⅱ(P〈0.01).Conclusion: There are an abnomal balance between hyper-coagulation in patients with gynecologic malignant tumor.
出处 《南通大学学报(医学版)》 2011年第3期190-191,共2页 Journal of Nantong University(Medical sciences)
关键词 恶性肿瘤 凝血功能 妇科 mlignant tumor coagulation function gynecology
  • 相关文献

参考文献8

二级参考文献20

  • 1林懿,林英城,林文照,王鸿彪,林穗玲,曾德,霍霞.纤维蛋白原水平在恶性肿瘤诊治中的临床意义[J].中国癌症杂志,2004,14(6):521-522. 被引量:9
  • 2程蓓,俞黎铭,叶大风.上皮性卵巢癌患者凝血功能测定及其临床意义[J].浙江医学,2005,27(7):490-492. 被引量:14
  • 3林粤,韩玲霞.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志,2006,15(5):636-637. 被引量:25
  • 4Usual E,Atalav F,Atikcan S,et al.Prognostic significance of hemostatic parameters in parptients with lung cancer.Respir Med,2004,98(2):93.
  • 5Von Tempelhoff GF, Dietrich M, Niemann F. Blood coagulation and thrombosis in patients with ovarian malignancy.Thromb Haemost, 1997,77(3):456.
  • 6Donati MB. Cancer and thrombosis. Haemostasis, 1994,24(2):128.
  • 7Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol, 1999, 75(3):397.
  • 8Den Ouden M, Ubachs JM, Stoot JE,et al. Thrombin-antithrombin Ⅲ and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scand J Clin Lab Invest, 1998, 58(7):555.
  • 9Uno K,Homma S,Satoh T,et al.Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer[J].Br J Cancer,2007,96(2):290-295.
  • 10Trousseau A.Phlegmasia alba dolens.Clinique Medicale de l'Hotel-Dieu de Paris London[J].New Sydenham Society,1865,3(1):94.

共引文献280

同被引文献60

  • 1熊春秋.妇科肿瘤患者凝血功能变化的临床分析[J].世界临床医学,2017,11(3):130-130. 被引量:3
  • 2赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析[J].华北煤炭医学院学报,2006,8(1):84-85. 被引量:13
  • 3袁建云,英立平.临床路径实施手册[M].北京:北京医科大学,中国协和医科大学联合出版社,2002:1-14.
  • 4赵建荣,张开资.恶性肿瘤患者不同阶段凝血功能及血小板变化分析[D].华北煤炭医学院学报,2013,12(10):284-285.
  • 5Wada H,Sase T,Yamaguchi M.Hypercoagulant states in malignant lymphoma[J].Exp Onco 1,2013,27 (3): 179-181.
  • 6Samarna M,Horellou H,Elalamy I,et al.D-dimet levels, constitution ahhrombophilia, and venous thrombosis prediction; clinical aspects and implications[J].Semin Vasc Med,2013,15(4):371-372.
  • 7Boisclair A,Lane T,Wilde A.A comparative evaluation of markers of active coagulation and/or fibrinolysis: thrombin antithrombin complex, D-dimer and Fibrinogen/fibrin Fragment Eantigen[J].Br Haenatol,2013,74(4) :471-472.
  • 8Gaddueci A.Pretretment plasma levels of fibrinopeptide-A(FPA), D-dimer(DD), and Yon Willebran of actor(VWF)in patients with ovary carcinoma[J].Gynecol oncol,2013,15(3):532-535.
  • 9Wada H,Sase T,Yamaguchi M. Hypercoagulant states in malignant lymphoma [ J]. Experimental Oneology ,2005,27 ( 3 ) : 179.
  • 10Samama MM, Horellou MH, Elalamy I, et al. D-dimer levels, constitu- tional thrombophilia, and venous thrombosis prediction:clinical aspects and implieations[J]. Seminars in Vascular Surgery,2005,5 (4) :371.

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部